Description

Roivant Sciences Unlocks A Multi-Indication Opportunity — Brepocitinib Moves Beyond Dermatomyositis!

Roivant Sciences reported financial results for the first quarter ended June 30, 2026, describing the period as relatively quiet while highlighting substantial portfolio progress and a busy upcoming catalyst calendar. Its main near-term focus is the potential launch of brepocitinib in dermatomyositis, expected imminently following priority FDA review. Brepocitinib demonstrated statistically significant clinical benefit across endpoints and received positive physician and patient feedback, positioning it to address substantial unmet need with limited treatment options. Roivant expects a “slow and steady” launch designed to build a broad foundation across additional indications, including non-infectious uveitis, cutaneous sarcoidosis, and lichen planopilaris, where pivotal trial enrollment is progressing well. Roivant initiated a Phase III study in cutaneous sarcoidosis ahead of schedule. Phase II data showed a notable magnitude of clinical benefit, supporting the pivotal program, with data expected in 2028.